Pharmaceutical Preparations
Standard Industrial Classification: SIC 2834
Industry Insider Sentiment Analysis
The Pharmaceutical Preparations sector (SIC 2834) acts as a critical barometer for broader economic health. Our real-time monitoring reveals total transactions. Monitoring "cluster buying" is one of the most reliable leading indicators for future sector performance. By analyzing aggregate data across this specific Standard Industrial Classification, investors can filter out individual company volatility and identify high-conviction trends. When multiple directors and officers within the same industry move capital simultaneously, it often signals an upcoming sector-wide revaluation or a fundamental shift in supply chain dynamics that has yet to be recognized by the broader public market.
| Filing Date | Trade Date | Ticker | Company | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-01-21 00:30 | 2026-01-16 | UTHR | UNITED THERAPEUTICS Corp | MALCOLM JAN | Director | SELL | $460.98 | 50 | $23,049 | 320 |
| 2026-01-21 04:18 | 2026-01-16 | IONS | IONIS PHARMACEUTICALS INC | HOUGEN ELIZABETH L | Officer | OPT+S | $75.22 | 12,922 | $971,993 | 126,307 |
| 2026-01-21 04:18 | 2026-01-16 | IONS | IONIS PHARMACEUTICALS INC | BENNETT C FRANK | Officer | OPT+S | $75.15 | 8,977 | $674,622 | 94,757 |
| 2026-01-21 00:33 | 2026-01-15 | DVAX | Dynavax Technologies Corporation | Novack David F | Officer | OPT+S | $15.64 | 114,000 | $1,782,960 | 63,344 |
| 2026-01-17 00:06 | 2026-01-15 | RAPP | Rapport Therapeutics, Inc. | Bredt David | Officer | SELL | $26.84 | 8,500 | $228,132 | 395,575 |
| 2026-01-16 23:42 | 2025-10-17 | MYNZ | MAINZ BIOMED N.V. | Donahue Kevin Michael | 10% owner | BUY | $402,000.00 | 643,850 | $258,827,700,000 | 643,850 |
| 2026-01-17 01:22 | 2026-01-15 | TERN | Terns Pharmaceuticals, Inc. | Burroughs Amy L. | Director, Officer | OPT+S | $37.07 | 68,749 | $2,548,601 | 288,976 |
| 2026-01-16 19:16 | 2026-01-13 | CLNN | Clene Inc. | Ugwumba Chidozie | 10% owner | SELL | $5.01 | 58,289 | $292,185 | 650,298 |
| 2026-01-17 00:07 | 2026-01-15 | IMRX | Immuneering Corp | Hall Brett Matthew | Officer | BUY | $4.57 | 2,298 | $10,502 | 376,496 |
| 2026-01-17 00:02 | 2026-01-14 | ACRV | Acrivon Therapeutics Inc. | Blume-Jensen Peter | Director, Officer | BUY | $1.68 | 49,000 | $82,124 | 2,095,771 |
| 2026-01-17 00:01 | 2026-01-14 | ACRV | Acrivon Therapeutics Inc. | Levy Adam D. | Officer | BUY | $1.70 | 8,832 | $14,999 | 20,983 |
| 2026-01-17 01:26 | 2026-01-15 | ORKA | Oruka Therapeutics, Inc. | Goncalves Joana | Officer | OPT+S | $31.81 | 7,000 | $222,704 | 1,518 |
| 2026-01-17 05:00 | 2026-01-14 | OLMA | Olema Pharmaceuticals, Inc. | Harmon Cyrus | Director | SELL | $29.12 | 3,489 | $101,600 | 737,770 |
| 2026-01-17 00:05 | 2026-01-15 | MIRM | Mirum Pharmaceuticals, Inc. | Ramasastry Saira | Director | OPT+S | $90.99 | 2,000 | $181,980 | 0 |
| 2026-01-16 21:05 | 2026-01-15 | ANAB | AnaptysBio Inc. | Marquet Magda | Director | OPT+S | $48.23 | 11,000 | $530,531 | 9,930 |
| 2026-01-15 14:05 | 2026-01-13 | GLSI | Greenwich LifeSciences, Inc. | Patel Snehal | Director, Officer, 10% owner | BUY | $29.83 | 1,800 | $53,694 | 5,604,102 |
| 2026-01-15 16:06 | 2026-01-13 | IMRX | Immuneering Corp | Neufeld Leah R | Officer | BUY | $4.15 | 2,626 | $10,906 | 25,970 |
| 2026-01-16 00:38 | 2026-01-13 | ACRV | Acrivon Therapeutics Inc. | Devroe Eric | Officer | BUY | $1.72 | 10,000 | $17,218 | 75,308 |
| 2026-01-16 00:20 | 2026-01-13 | BIOA | BioAge Labs, Inc. | Fortney Kristen | Director, Officer | SELL | $18.12 | 233,107 | $4,223,036 | 976,949 |
| 2026-01-16 03:07 | 2026-01-13 | MLYS | Mineralys Therapeutics, Inc. | Rodman David Malcom | Officer | OPT+S | $32.66 | 19,076 | $623,114 | 50,437 |
| 2026-01-16 05:00 | 2026-01-13 | OLMA | Olema Pharmaceuticals, Inc. | Kovacs Shane William Charles | Officer | SELL | $28.70 | 103,822 | $2,980,055 | 139,727 |
| 2026-01-16 00:34 | 2026-01-13 | APLS | Apellis Pharmaceuticals Inc. | Chopas James George | Officer | SELL | $22.19 | 873 | $19,369 | 52,595 |
| 2026-01-16 00:33 | 2026-01-13 | APLS | Apellis Pharmaceuticals Inc. | DeLong Mark Jeffrey | Officer | SELL | $22.19 | 1,780 | $39,493 | 83,058 |
| 2026-01-16 00:32 | 2026-01-13 | APLS | Apellis Pharmaceuticals Inc. | Deschatelets Pascal | Officer | SELL | $22.19 | 2,277 | $50,520 | 1,158,219 |
| 2026-01-16 00:31 | 2026-01-13 | APLS | Apellis Pharmaceuticals Inc. | Francois Cedric | Director, Officer | SELL | $22.19 | 10,186 | $225,999 | 321,419 |
| 2026-01-16 00:30 | 2026-01-13 | APLS | Apellis Pharmaceuticals Inc. | Nicholson Nur | Officer | SELL | $22.19 | 2,618 | $58,086 | 81,046 |
| 2026-01-16 00:29 | 2026-01-13 | APLS | Apellis Pharmaceuticals Inc. | Sullivan Timothy Eugene | Officer | SELL | $22.19 | 3,856 | $85,554 | 107,080 |
| 2026-01-16 00:28 | 2026-01-13 | APLS | Apellis Pharmaceuticals Inc. | Watson David O. | Officer | SELL | $22.19 | 5,780 | $128,242 | 98,838 |
| 2026-01-16 01:22 | 2026-01-13 | HOWL | Werewolf Therapeutics, Inc. | EVNIN LUKE | Director | SELL | $0.56 | 111,227 | $61,787 | 2,198,642 |
| 2026-01-16 00:22 | 2026-01-13 | BIOA | BioAge Labs, Inc. | GOLDSTEIN DOV A MD | Officer | OPT+S | $19.70 | 27,000 | $531,827 | 22,408 |
| 2026-01-16 00:32 | 2026-01-15 | UTHR | UNITED THERAPEUTICS Corp | MAHON PAUL A | Officer | OPT+S | $469.89 | 8,300 | $3,900,122 | 36,781 |
| 2026-01-16 02:24 | 2026-01-13 | PAHC | PHIBRO ANIMAL HEALTH CORP | BENDHEIM JACK | Director, Officer, 10% owner | SELL | $40.31 | 14,134 | $569,753 | 44,525 |
| 2026-01-14 14:05 | 2026-01-12 | GLSI | Greenwich LifeSciences, Inc. | Patel Snehal | Director, Officer, 10% owner | BUY | $27.54 | 2,900 | $79,866 | 5,602,302 |
| 2026-01-14 16:10 | 2026-01-12 | IMRX | Immuneering Corp | Feinberg Peter | Director | BUY | $4.35 | 20,000 | $86,904 | 135,441 |
| 2026-01-15 05:30 | 2026-01-12 | OLMA | Olema Pharmaceuticals, Inc. | Myles David C. | Officer | OPT+S | $28.25 | 110,000 | $3,107,225 | 542,761 |
| 2026-01-15 05:00 | 2026-01-12 | ROIV | Roivant Sciences Ltd. | Venker Eric | Officer | OPT+S | $21.92 | 200,000 | $4,384,000 | 1,654,597 |
| 2026-01-15 00:26 | 2026-01-12 | QURE | uniQure N.V. | Gut Robert | Director | OPT+S | $24.62 | 25,613 | $630,482 | 32,342 |
| 2026-01-15 01:12 | 2026-01-12 | VSTM | Verastem, Inc. | Paterson Dan | Director, Officer | SELL | $7.16 | 10,321 | $73,898 | 400,104 |
| 2026-01-15 01:11 | 2026-01-12 | VSTM | Verastem, Inc. | Calkins Daniel | Officer | SELL | $7.16 | 5,039 | $36,079 | 104,719 |
| 2026-01-15 02:20 | 2026-01-12 | AKTS | Akoustis Technologies Inc. | Foley Todd | Director, 10% owner | BUY | $18.00 | 232,870 | $4,191,660 | 4,235,403 |
| 2026-01-14 20:56 | 2026-01-13 | SER | Serina Therapeutics, Inc. | Moreadith Randall | Officer | OPT+S | $2.50 | 6,500 | $16,253 | 0 |
| 2026-01-15 01:25 | 2026-01-12 | OMER | OMEROS CORP | Borges David J. | Officer | OPT+S | $12.52 | 60,000 | $750,912 | 0 |
| 2026-01-15 00:23 | 2026-01-12 | ALNY | Alnylam Pharmaceuticals Inc. | Garg Pushkal | Officer | SELL | $362.87 | 1,510 | $547,929 | 22,511 |
| 2026-01-15 00:23 | 2026-01-12 | ALNY | Alnylam Pharmaceuticals Inc. | Greenstreet Yvonne | Director, Officer | SELL | $362.86 | 9,577 | $3,475,156 | 78,411 |
| 2026-01-15 00:22 | 2026-01-12 | ALNY | Alnylam Pharmaceuticals Inc. | Poulton Jeffrey V. | Officer | SELL | $362.87 | 2,780 | $1,008,766 | 57,465 |
| 2026-01-15 00:22 | 2026-01-12 | ALNY | Alnylam Pharmaceuticals Inc. | Tanguler Tolga | Officer | SELL | $362.87 | 1,510 | $547,927 | 29,728 |
| 2026-01-15 00:21 | 2026-01-12 | ALNY | Alnylam Pharmaceuticals Inc. | Fitzgerald Kevin Joseph | Officer | SELL | $367.37 | 3,800 | $1,395,992 | 21,264 |
| 2026-01-15 02:19 | 2026-01-12 | AKTS | Akoustis Technologies Inc. | MPM BIOVENTURES 2018, L.P. | 10% owner | BUY | $18.00 | 1,112,777 | $20,029,986 | 10,260,064 |
| 2026-01-15 02:17 | 2026-01-12 | AKTS | Akoustis Technologies Inc. | GADICKE ANSBERT | 10% owner | BUY | $18.00 | 1,112,777 | $20,029,986 | 10,260,064 |
| 2026-01-15 02:14 | 2026-01-13 | ANIP | Ani Pharmaceuticals Inc. | Cook Meredith | Officer | SELL | $84.33 | 500 | $42,165 | 74,374 |
Sector-Wide Insider Alpha
Analyzing insider movements across the Pharmaceutical Preparations sector provides a macro-view of executive conviction. When multiple leaders in different companies within the same SIC code (2834) simultaneously buy shares, it often indicates an industry-wide undervaluation or a positive shift in market cycles.
SEC Filings in Pharmaceutical Preparations
Every transaction in the Pharmaceutical Preparations industry is reported via Form 4 disclosures. By filtering these filings by industry, investors can detect institutional-scale sentiment shifts before they are reflected in broader market indices, following the capital flow of those with intimate industry knowledge.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.